All In Biotech

Drug Trial Radar · NCT01035229

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

A Randomized Phase III, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Everolimus (RAD001) in Adult Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment - The EVOLVE-1 Study

Last checked: Nov 20, 2026Latest source record: Sep 22, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 546 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

546

Actual

Start

Apr 2010

Primary completion

Oct 2013

Study completion Oct 2013

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 18, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare treatment with RAD001 plus best supportive care (BSC) to placebo plus BSC in patients with advanced HCC whose disease progressed while on or after sorafenib treatment or who are intolerant to sorafenib.

Conditions

  • Carcinoma

Interventions

  • EverolimusDrug

    Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.

  • Everolimus PlaceboDrug

    Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.

  • Best Supportive Care (BSC)Other

    BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: When 454 OS events were observed

Locations

131 sites in 18 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group Dept of Highlands Oncology Grp

    Fayetteville, Arkansas

  • Compassionate Cancer Care Medical Group CCCMG

    Fountain Valley, California

  • University of California San Diego - Moores Cancer Center SC - 3

    La Jolla, California

  • California Pacific Medical Center California Pacific Med

    San Francisco, California

  • Rocky Mountain Cancer Centers RMCC - Denver-Midtown (4)

    Greenwood Village, Colorado

  • Queen's Medical Center Queens Cancer Center

    Honolulu, Hawaii

  • The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Dept. of SKCC @ JHU

    Baltimore, Maryland

  • Massachusetts General Hospital Dept. of Mass General Hospital

    Boston, Massachusetts

  • Midwest Cancer Care Physicians Research Medical Center

    Kansas City, Missouri

  • VA Sierra Nevada Health Care System Dept. of VA Sierra Nevada HCS

    Reno, Nevada

  • University of Rochester Medical Center Rochester

    Rochester, New York

  • Northwest Cancer Specialists Rose Quarter Cancer Center

    Portland, Oregon

  • St. Luke's Hospital and Health Network St. Luke's Cancer Network (2)

    Bethlehem, Pennsylvania

  • Texas Cancer Center - Abilene

    Abilene, Texas

  • Methodist Charlton Cancer Center Methodist

    Dallas, Texas

  • University of Texas Southwestern Medical Center DeptofSimmons Cancer Center(3)

    Dallas, Texas

  • Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio

    San Antonio, Texas

  • Blue Ridge Research Center at Roanoke Neurological Center Blue Ridge Cancer Care

    Roanoke, Virginia

  • University of Washington Cancer Care SC

    Seattle, Washington

  • Novartis Investigative Site

    Camperdown, New South Wales, Australia

  • Novartis Investigative Site

    Kogarah, New South Wales, Australia

  • Novartis Investigative Site

    Westmead, New South Wales, Australia

  • Novartis Investigative Site

    Heidelberg, Victoria, Australia

  • Novartis Investigative Site

    Parkville, Victoria, Australia

  • Novartis Investigative Site

    Graz, Austria

  • Novartis Investigative Site

    Innsbruck, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Edegem, Belgium

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    London, Ontario, Canada

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Guangzhou, China

  • Novartis Investigative Site

    Nanjing, Jiangsu, China

  • Novartis Investigative Site

    Xi’an, Shanxi, China

  • Novartis Investigative Site

    Chengdu, Sichuan, China

Showing 40 of 131 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.